论文部分内容阅读
目的:研究蒙药乳腺-I(M-I)号对乳腺增生模型大鼠雌激素(E2)及雌激素受体(ERα)mRNA表达水平的调节作用。方法:雌性未孕大鼠肌注苯甲酸雌二醇(0.5 mg·kg-1·d-1)25天,随后肌注黄体酮(4 mg·kg-1·d-1)5天复制乳腺增生动物模型。实验分组及给药:正常对照组、模型对照组、M-I号低、高剂量组(别给予M-I号0.5 g·kg-1、3.0 g·kg-1灌胃)、阳性对照组(给予三苯氧胺1.8 mg/kg灌胃)。实验结束后,取大鼠乳腺组织检测乳腺组织中E2及ERαmRNA表达情况。结果:模型对照组与正常对照组比较,ERα含量和ERαmRNA表达均有显著的增加(P<0.01),M-I号低、高剂量可显著降低乳腺组织中ERαmRNA的表达。结论:M-I号能有效降低模型动物的E2及ERαmRNA表达,使乳腺组织对E2的敏感性降低而达到治疗作用。
Objective: To investigate the regulatory effect of Mongolian medicine M-I on estrogen (E2) and estrogen receptor (ERα) mRNA expression in mammary gland hyperplasia model rats. METHODS: Female un-pregnant rats were intramuscularly injected with estradiol benzoate (0.5 mg · kg-1 · d-1) for 25 days, then intramuscular injection of progesterone (4 mg · kg-1 · d-1) Proliferation animal model. The experimental groups and administration: normal control group, model control group, low MI and high dose group (intragastric administration of MI 0.5 g · kg -1 and 3.0 g · kg -1), positive control group (tamoxifen 1.8 mg / kg orally). After the experiment, take the rat mammary gland tissue to detect the expression of E2 and ERαmRNA in breast tissue. Results: Compared with the normal control group, ERα and ERαmRNA expression were significantly increased in the model control group (P <0.01). The low and high doses of M-I significantly decreased the expression of ERαmRNA in breast tissues. Conclusion: M-I can effectively reduce the expression of E2 and ERαmRNA in the model animals, and reduce the sensitivity of breast tissue to E2 to achieve the therapeutic effect.